Silence Therapeutics Continues Transformation, Improves US Visibility
Lists On NASDAQ, Starts Clinical Studies
The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.
